• OPEN AN ACCOUNT
Indian Indices
Nifty
22,502.00 35.90
(0.16%)
Sensex
74,005.94 88.91
( 0.12%)
Bank Nifty
48,199.50 83.85
( 0.17%)
Nifty IT
33,438.75 56.90
( 0.17%)
Global Indices
Nasdaq
16,685.97 -12.35
(-0.07%)
Dow Jones
40,003.59 134.21
(0.34%)
Hang Seng
19,553.61 177.08
(0.91%)
Nikkei 225
38,787.38 -132.88
(-0.34%)
Forex
USD-INR
83.47 0.01
(0.01%)
EUR-INR
90.76 0.22
(0.25%)
GBP-INR
105.79 0.36
(0.34%)
JPY-INR
0.54 0.00
(0.51%)

EQUITY - MARKET SCREENER

GVP Infotech Ltd
Industry :  Computers - Software - Medium / Small
BSE Code
ISIN Demat
Book Value()
532600
INE382T01030
10.2650182
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
GVPTECH
153.57
175.08
EPS(TTM)
Face Value()
Div & Yield %
0.07
2
0
 

jubilant life sciences ltd
Jubilant Pharmova announces conclusion of Montreal facility audit by US FDA
Apr 25,2024

The said facility is operated by Jubilant Draximage Inc., a subsidiary of Jubilant Pharma (JPL), which is a wholly-owned subsidiary of Jubilant Pharmova. JPL is an ntegrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 46 radio-pharmacies in the US; allergy immunotherapy, contract manufacturing of sterile injectables and non-sterile products and solid dosage formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies.

'The USFDA has issued 5 observations pursuant to the completion of audit. The company will submit an action plan on the observations,' Jubilant Pharmova said in a statement.

Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, CDMO of sterile injectable, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses.

The pharmaco has reported a net profit of Rs 66 crore in Q3 FY24 as against a net loss of Rs 16 crore in Q3 FY23. Total income increased by 10% YoY to Rs 1,713 crore during the period under review.

The scrip rose 0.25% to currently trade at Rs 684.25 on the BSE.